Search
TD-0903
go.drugbank.com/drugs/DB16463InvestigationalTD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants … with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)
KOS-1584
go.drugbank.com/drugs/DB05903InvestigationalEpothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors.
Synonyms: (E)-9,10-Dehydroepothilone D, (E)-9,10-Didehydroepothilone DISIS 325568
go.drugbank.com/drugs/DB06099InvestigationalIt was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.
Nadide
go.drugbank.com/drugs/DB14128InvestigationalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Siltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.
Etizolam
go.drugbank.com/drugs/DB09166InvestigationalInitially introduced in 1983 in Japan as treatment for neurological conditions such as anxiety and sleep disorders, etizolam is marketed in Japan, Italy and India. … It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.
International brands: E1Pegdinetanib
go.drugbank.com/drugs/DB05931InvestigationalCT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis
UC-781
go.drugbank.com/drugs/DB05871InvestigationalUC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.